Strategic consolidation Selexis SA and KBI Biopharma are consolidating operations under the KBI Biopharma brand, signaling a unified CDMO offering that could simplify client partnerships and cross-sell services such as development, manufacturing, and fill-finish solutions.

Awarded capability Recent recognition as Fill-Finish CDMO of the Year and Best in Class for Cultural Fit positions KBI Biopharma as a credible partner for biologics development and manufacturing, a strong differentiator in competitive pitches to biotech clients.

New business levers Active collaboration with external biotech entities (Kalaris Therapeutics, Alanis Therapeutics) for clinical supply manufacturing and preclinical development indicates potential for scalable outsourcing programs and multi-site manufacturing arrangements.

Global reach, local impact Participation in major industry events like BIO International Convention and existing cloud-based tech stack show readiness to engage global customers while leveraging digital platforms for prospect reach and program management.

Low revenue signal Reported revenue range is $0-1M with a lean employee base, suggesting a growth-focused organization open to new partnerships, early-stage programs, and scalable CDMO engagements as they expand capabilities.